Novo Nordisk stock: FDA rejects weekly basal insulin bid

Company: Novo Nordisk A/S
ISIN: DK0062498333
Trading venue: Lang &amp; Schwarz
Quoted price: 37.19 euros at 17:13 CET on November 13, 2026

Published on 11/13/2026 at 17:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock faces a US pipeline setback after the FDA rejected a once-weekly basal insulin application. The decision blocks a near-term launch.

Regulatory setback for weekly insulin

The FDA rejected an application for a once-weekly basal insulin intended to reduce injection frequency.
The decision blocks a near-term US launch for the pipeline project and raises execution pressure across Novo Nordisk's diabetes portfolio.

Novo-Nordisk, DK0062498333, Illustration mit AI erstellt.

Novo Nordisk faces a fresh US regulatory setback. On Friday, November 13, Pharmaphorum reported that the Food and Drug Administration had rejected the company's application for a once-weekly basal insulin.

What the FDA decision means

The application covered a basal insulin designed to reduce the number of injections required by people with diabetes. The rejection blocks a near-term US launch for that project and adds another execution challenge to Novo Nordisk's diabetes portfolio.

Why the pipeline detail matters

Once-weekly dosing is intended to simplify treatment compared with daily basal insulin. The regulatory decision therefore affects both the timing of a potential product launch and the company's ability to advance another convenience-focused treatment option.